Navigation Links
Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
Date:11/9/2009

BEND, Oregon, November 9 /PRNewswire/ -- Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.

Through this new collaboration, Vertex will utilize Bend's formulation development and manufacturing services for specific projects and clinical trials, with the goals of both enhancing the delivery of Vertex compounds and supporting the progression of certain Vertex product candidates through clinical development.

The collaboration between Bend Research and Vertex is designed to leverage the fundamental scientific capabilities of each company to solve formulation and process-development challenges and to produce commercial drug products that are optimized for therapeutic benefit.

"It's a great opportunity for both companies," Bend Research CEO Rod Ray explained. "We are excited to be working with Vertex. We share their commitment to delivering breakthrough therapies based on cutting-edge science. Having two great teams working side by side is a powerful combination - we look forward to a long and fruitful relationship."

Vertex's Executive Vice President of Global Research and Development and Chief Scientific Officer, Peter Mueller, added, "Our collaboration with Bend Research exemplifies Vertex's commitment to the treatment of serious diseases through cutting-edge science and innovative technologies. We believe Bend's technologies and expertise will provide Vertex with important scientific capabilities that will support our drug development efforts."

Bend Research is making its multidisciplinary team of scientists and engineers available to companies for solving tough formulation a
'/>"/>

SOURCE Bend Research Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...therlandsandJOHANNESBURG,November25/PRNewswire/--,...overyannouncedtoday,thattheyhavesignedacollaborati... , Pyxis,sworldclasscomputationalchemistryand...ervicedivisiontoprovidemedicinaland,syntheticchemi...nationalclientnetwork.iThembaPharmaceuticalsandPyx...
(Date:11/24/2009)...Nov.24/PRNewswire/-- ,, WHAT:RomHoubens,aBelgia...toaccident,wasactuallyfullyconsciousandawakeduring...nt.TheDynaVoxEyeMaxwasfeaturedinthesegmenttoillust...nscanunlockcommunication. ,, WHEN:GoodMorningAm...w.dynavoxtech.com ,, WHO:RomHoubenswasaneng...
(Date:11/24/2009)...v.24/PRNewswire-FirstCall/--AnadysPharmaceuticals,...atthe21stAnnualPiperJaffrayHealthcareConferenceonT...econferenceisbeingheldatTheNewYorkPalaceHotel.Stev...Anadys,willprovideanoverviewofAnadysanditsclinical...oratepresentationwillbesimultaneouslywebcastandcan...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 1Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 2Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 3Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 4Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 5WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 1WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 2WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 3Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 1Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 2Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 3
(Date:11/26/2009)...tions announces a highly effective and unconventio...g to make an economic recovery. , ... the type of challenge that could send ailing holi...David Benton, business growth expert and author of... The Rfactor Intensive . “Fear is one of ...
(Date:11/25/2009)...e-FirstCall/-- OnyxPharmaceuticals,Inc.(Nasdaq: O...oreventsinDecember: ,, ASHBriefing ,, ...cipalinvestigatorswilldiscussdatapresentationssurr...lemyeloma,asfeaturedatthe51stAmericanSocietyofHema...LA.Theteleconferencewillbeginat9:00a.m.CT/10:00a.m...
(Date:11/25/2009)...-USNewswire/--AnarticlebyJanetWoodcock,M.D.,direct...led"ADifficultBalance-PainManagement,DrugSafety,an...ndJournalofMedicine. ,, (Logo: http://www.newsc...article,WoodcockdiscussesFDAeffortstostrikeabalanc...managingtherisksposedbyvariousanalgesics.Asexample...
(Date:11/25/2009)... who were treated with cisplatin-based chemotherap...ical side effects and Raynaud-like phenomena, than...ding to a new study published online November 25 i..., Marianne Brydy, M.D., of the Department of Onc...orway, and colleagues conducted a cross-sectional ...
(Date:11/25/2009)...o draw definite conclusions, experts say, , ...iabetic patients with blocked coronary arteries, t...e year whether patients undergo bypass surgery or ...ort. , Bypass surgery has been the standard tre...disease. However, less invasive approaches such as...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3
...common, naturally occurring virus that attacks can...ls is being studied as a possible treatment for ma... called gliomas. Researchers at Cedars-Sinai Medic...the virus in its natural state. It commonly infect...
...and African plants are being used by Queensland re...o treat chronic pain. , Professor David Craik an...r Bioscience have received $218,275 from the Natio...he molecule they have developed have shown that it...
...mon and severe symptom reported by middle-aged wom... into the menopause, according to a study in the A...sing. , Researchers at the University of Arizona ...s. Their average age was 49 and they had all exper...
...Xinhua-PRNewswire-FirstCall/ --,China RuiTai Inter...RUI),(,China RuiTai, or ,the Company,), a leading ...ts in the People,s Republic of China (,PRC,),today...n -- Gross profit increased 33.4% to $11.9 millio...
...rience in both healthcare and human ...Precyse Solutions, the leader in,driving peak perf...,departments, today announced the appointment of K...f Human Resources,and Administration. With over 25...
...verwhelmingly want their next President to focus m...ng universal healthcare, and stemming the,outsourc...igrants to live,and work in the U.S., according to...ing of 1,125 working,Americans between April 4 and...
Other Medicine News:Health News:Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells 2Health News:Cone snails and plants used to develop oral drug for pain 2Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 2Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 3Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 2Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 3Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 4Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 5Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 6Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 7Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 8Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 9Health News:Precyse Solutions Appoints Karen Heisler as New Corporate Vice President, Human Resources 2Health News:Americans Want Next President to Focus More on Saving U.S. Jobs and Healthcare; Less on Immigration Reform 2Health News:Americans Want Next President to Focus More on Saving U.S. Jobs and Healthcare; Less on Immigration Reform 3
Slimtine S
M 3.2 J Unipolar Atrial "J" Lead
VascoTip P 9/60 PU S
VascoTip P 9/60 M
Medicine Products: